Visugromab (Powder)
Based on 2 publication(s) in Google Scholar
Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
For research use only. We do not sell to patients.
- CAS No.: 2556646-63-8
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Visugromab (Powder)
More
Customer Validation & Images
-
ELISA
-
Cell Proliferation/Viability Assay
Biological Activity
|
GDF15 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG4-kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2556646-63-8
-
SMILES
[Visugromab (Powder)]
-
Synonyms
CLT-002 (Powder)
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Mol Cell Biochem
Senescence of endothelial cells promotes phenotypic changes in adventitial fibroblasts: possible implications for vascular aging. [Abstract]2024 May 14. PMID: 38743322
Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 May 14. [Abstract]
GDF-15 protein level measured by ELISA in CM following 1h incubation with different concentrations of Visugromab (0.625-20 μg/mL). 20 μg/mL was selected as the effective neutralization concentration.
Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 May 14. [Abstract]
The quantification of EdU positive nuclei as a percentage of all nuclei for hAdv cultured in control conditions (hAdv) or in the presence of Visugromab (20 μg/ml) in culture medium. Addition of Visugromab directly to hAdv cells culture medium resulted in decreased proliferation rate of the cells.
-
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz